Pembrolizumab Combination for Metastatic NSCLC Upgraded to Full FDA Approval

FDA upgraded the approval of pembrolizumab in combination with pemetrexed and platinum chemotherapy as a first-line treatment for patients with metastatic, nonsquamous NSCLC with no EGFR or ALK genomic tumor aberrations from accelerated to regular approval.

from Latest articles from Cancer Therapy Advisor News https://ift.tt/2wqJ9Nh